The loss of market share we are already seeing for on-market cell therapy products is a result of in-class competitors for the same target and indication from rival innovator companies, not copycat products with identical CAR sequences.
Evolve is a specialist pharmaceutical and biotechnology IP firm. Our cell and gene therapy practice is led by Rose Hughes, formerly Director, Patents at AstraZeneca and IP lead for its biopharma cell therapy group. Rose holds a PhD in immunology and has led IP due diligence and deal negotiation on high-value cell therapy transactions.
Loss of exclusivity for a cell therapy is rarely set by the expiry of a narrow product patent or the end of regulatory exclusivity. It is set by competitors, whether another product of the same modality or a different modality reaching the same indication. The durable IP position is built around the features that drive efficacy and safety. Read more: Patents versus regulatory exclusivity | Bridging the innovation and commercialisation gap
Process patents filed early may get designed around, change over time, become prior art against your own improvements and be difficult to enforce. Early manufacturing innovation is often better held as a trade secret. We help separate company know-how, formal trade secrets and the features worth patenting. Read more: Beyond the process | T 0868/23
If the definitions are too narrow, the clinical product can fall outside the claimed markers. If they are too broad, the claim is exposed to insufficiency, and inaccurate or outdated definitions can undermine validity and scope. Read more: Defining the undefinable | A new way to define T cells
Advanced therapies open up IP opportunities that other technologies do not. Treatment protocol inventions, broader platform claims and field-blocking IP around targets, delivery and cell types can protect a market far better than a claim to one construct. Read more: T 1555/23 | The universal cell therapy revolution
Investors and pharma partners want to know how long the market is protected and why a competitor cannot design around. Answering that means knowing which IP is actually valuable. With no biosimilar pathway, the usual formula of patent expiry or regulatory exclusivity does not work for cell therapies. We forecast the protected period by weighing in-class and out-of-class competitors, labels, manufacturing capacity and the strength of treatment and platform IP, then turn a complex, layered estate into a clear account of its value, with visual tools such as the Ammonite Chart where they help.
Read more: Patents versus regulatory exclusivity | Thinking beyond the sequence | Investors | Bridging the innovation and commercialisation gap
Advanced therapies are moving from end-of-line treatments for a few patients towards durable, scalable medicines for many. That shift will come from new targets and indications, allogeneic and in vivo products, and better delivery and manufacturing, and each step creates new IP and new competition.
Our practice is led by Rose Hughes, formerly Director, Patents at AstraZeneca and IP lead for its biopharma cell therapy group, who has led IP due diligence and deal negotiation on high-value cell therapy transactions. We have sat on the client side of the table, communicated IP risk and opportunity to company boards and senior executives, and supported successful investor interactions. We understand the complexities of manufacturing, regulation and commercialisation for advanced therapies.
Our team includes scientific experts in immunology, viral vectors, biochemistry and polymer chemistry, with doctoral research in vector design and delivery, a PhD in human macrophage biology and industry experience in antibody discovery at UCB. We draft and prosecute claims to CARs, binders, engineered cells, defined cell populations, lentiviral vectors, lipid nanoparticles and RNA cargo, and to newer modalities such as CAR-macrophages.
Read more: CAR-T cell therapies | Gene therapies | mRNA therapeutics | CAR-M cell therapy
Our AI tools: Darwin (drafting) | Gilbert (quality)
We are experts in oncology, autoimmune disease and neuroscience, and understand how the IP strategy differs between them, from the competing modalities and patient populations to the dosing, conditioning and endpoints that support new clinical filings. Rose Hughes was formerly Director, Patents at AstraZeneca and IP lead for its biopharma cell therapy department, covering autoimmune CAR-T and regenerative medicine programmes, and IP lead for clinical oncology CAR-T programmes.
Read more: The first CAR-T for a solid tumour | The universal cell therapy revolution
Stem cell and regenerative cell therapy products often face objections that they are natural products, or that they fall within exclusions for human embryos or methods of treatment. We have experience navigating these subject matter eligibility objections in patent offices around the world, and in defining heterogeneous cell populations in claims that hold.
Read more: Regenerative cell therapies | Restem v Jadi Cell | T 1259/22
Our AI tools: Popper (prosecution)
In vivo CAR-T, LNPs and viral vectors are crowded, fast-moving fields where new filings, clinical data and deals arrive every month. We provide our clients with competitive landscape analysis so freedom to operate, patentability and partnering decisions rest on today’s picture. Knowing the landscape if crucial for making the right filing decision.
Read more: Overcoming FTO and patentability challenges | Navigating the complex LNP IP landscape | Albert: AI-powered competitive intelligence
Our AI tools: Albert (validity and competitive intelligence) | Ammonite Chart (portfolio visualisation)
In cell and gene therapy, the IP is often what is being bought. Big pharma is acquiring technology platforms capable of generating a pipeline of products rather than single drug candidates: AbbVie’s $2.1 billion acquisition of Capstan Therapeutics, AstraZeneca’s acquisition of EsoBiotec for up to $1 billion, and Eli Lilly’s agreement to acquire Kelonia Therapeutics for up to $7 billion. Together, these three deals are worth up to ten billion dollars.
What makes a platform valuable to an acquirer is layers of protection that a competitor cannot simply design around:
We have run IP due diligence and negotiated IP terms on the in-licensing side of a $2 billion+ autoimmune cell therapy deal and a $4.5 billion antibody platform collaboration, directed the out-licensing of a whole neuroscience portfolio including gene therapy assets, and handled the IP work on a $150 million non-dilutive financing and an in vivo CAR-T licence. We help companies build that layered estate before diligence starts, forecast loss of exclusivity realistically, and explain the value of their IP to investors and pharma partners in terms they can rely on.
Read more: Due diligence | Investors | Patents versus regulatory exclusivity | The great consolidation | Navigating the complex LNP IP landscape
Our AI tools: Cassandra (due diligence) | Ammonite Chart (portfolio visualisation)
In vivo CAR-T combines a delivery vehicle, a targeting moiety, a cargo and a CAR, and each has its own crowded landscape. We advise on:
Our team has handled the IP work on an in vivo CAR-T licence for a Nasdaq-listed clinical-stage biotech. Our team combines experts in immunology, viral vectors, polymer chemistry and nucleic acids.
Read more: In vivo CAR-T | The great consolidation
Our AI tools: Albert (competitive intelligence) | Ammonite Chart (landscape visualisation)
In cell therapy the manufacturing process and the product are different assets. Process patents can be designed around, become prior art against your own improvements and be hard to enforce, so early manufacturing innovation is often better held as a managed trade secret.
We help CDMOs, biotechs and pharma companies decide what belongs where:
We also help companies protect their confidential information in deal negotiations, collaborations and manufacturing relationships, so that what is disclosed to a partner or CDMO is controlled, recorded and covered by the right terms.
Read more: Beyond the process | T 0868/23
Our AI tools: Franklin (publication review)
Several layers, which arrive at different times:
Regulatory exclusivity, patent term extensions and SPCs sit alongside these and extend the protected period. Much of the clinical and process IP is generated by the programme itself and can be claimed from data a company already holds.
Read more: T 1555/23 | Bridging the innovation and commercialisation gap | Beyond the process | Patents versus regulatory exclusivity
A general firm can file a cell therapy patent. A specialist will see which patents to file, and when. Knowing the industry is crucial. Cell and gene therapy is complex, fast-moving and different from conventional modalities such as small molecules and antibodies, so the usual approaches to protection and loss of exclusivity do not transfer.
You need someone who understands the commercial, regulatory and scientific challenges of these products and how they fit with the IP: how manufacturing and release criteria shape the claims, how regulatory interactions affect filing timing, how in-class competitors erode the market, and how deals are valued. Cell therapy IP turns on defining a highly complex product, separating process from product, capturing clinical IP from early data and forecasting loss of exclusivity against fast followers. It helps to have attorneys who understand the immunology, the vectors and the deal dynamics, and who have done the job in-house.
We are a team of patent directors and attorneys who have managed global IP portfolios in-house. Patent strategy for pharma has to take account of the global strategy from day one. We can advise on multijurisdictional IP strategy and align filing footprints and priorities to the commercial plan. We draft applications for priority filings in US and Europe, can advise on navigating global patentability, grace period provisions and prior use considerations. We currently act as fractional IP counsel for US and European-based clients.
Read more: International IP counsel | Oppositions and appeals
Yes. As fractional IP counsel, one of our patent directors acts as your head of IP for an agreed number of days a month, reporting to the board, sitting in R&D and regulatory meetings and negotiating IP terms. Rose Hughes currently acts as lead IP counsel to a Nasdaq-listed clinical-stage cell therapy company.
Read more: Fractional IP counsel
With a layered claim set. Product claims to the CAR, the binder and the engineered cell, supported by sequence and functional data, sit alongside method of treatment claims for the indications, dosing and patient groups, and process claims where the process can be detected.
The US and Europe then need different handling. In Juno v Kite the US Federal Circuit held a broad CAR claim invalid for lack of written description, so broad product claims to a genus of binders need substantial support. Method of treatment claims can fare better: in Teva v Eli Lilly the court upheld treatment claims to a known class of humanised antibodies, disclosed with only one humanised example. The EPO asks whether the therapeutic effect is credible across the whole claim, and post-published data can undermine a broad functional claim. The claim set has to be drafted to survive both.
Read more: Juno v Kite | Teva v Eli Lilly
Usually not as long as a patent expiry date or regulatory exclusivity suggests. There is no agreed biosimilar pathway for CAR-T, so the threat is the fast follower, an in-class competitor with a different binder or another modality aimed at the same indication. Yescarta’s US regulatory exclusivity runs to 2029, yet its revenue fell 5% between 2024 and 2025, probably in part because of Breyanzi, which has an entirely different CAR sequence, and T cell engagers in the same indication.
The protected period is set by competitors. Patents on the method of treatment, dose, patient subpopulation and treatment protocol often protect the market far better than a patent on the binder sequence alone, and broad, non-sequence-limited CAR-T patents are now being asserted between competitors at the Unified Patent Court.
Read more: Patents versus regulatory exclusivity | Thinking beyond the sequence
Often not on its own. Process claims are designed around, become obsolete as the process changes and are hard to enforce because infringement cannot be seen in the finished product. Where the process really is the advantage, a managed trade secret is usually better. Features a competitor could arrive at independently, or that can be reverse engineered, are often still worth patenting, so most companies need a hybrid strategy.
Where you do patent, plan for change. In T 0868/23 a CAR-T manufacturing claim was tied to specific activation conditions, and the EPO’s strict approach to added matter makes it hard to amend towards the parameters a process ends up using. An early filing can also become prior art against your own improvements. Applications need fallback positions for each parameter and combination you might later need.
Read more: T 0868/23 | Beyond the process
Not necessarily. A novel CAR can still sit inside a broader granted right, and patents on targeting molecules cover the molecule per se, so an antibody, ADC or bispecific patent on your target can block a cell therapy. With CAR-T now approved in a solid tumour, the competition for a target often comes from other modalities, and scFv binders may be reused across them. The vector, payload, process and cell source need clearing too. We can conduct initial landscape reviews, sequence and lipid structure searches and advise on patentability and infringement in this complex field.
Read more: IP strategy for cell therapy: FAQs | The first CAR-T for a solid tumour
As fractional in-house IP counsel we support portfolio strategy, report IP risks and opportunities to the board, sit in the R&D and regulatory conversations where filing timing is actually decided, and negotiate IP term sheets. Rose Hughes currently acts as lead IP counsel to a Nasdaq-listed clinical-stage cell therapy company, directing its IP strategy.
We act as fractional in-house IP counsel, so this thinking is available from seed stage. Investors and acquirers ask how long the market is protected and why a competitor cannot simply design around. We help our clients answer both questions so they can be successful in diligence and partnering.
“Rose provides rapid, expert IP strategy advice in cell and gene therapy, combining strong sector knowledge with the ability to quickly understand complex technologies.”
We are happy to have an informal conversation about your programme, with no obligation. You can read more about Rose Hughes, who leads our cell and gene therapy practice, and the rest of our team. We also write a regular newsletter on pharma and biotech IP.